Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“Pembro + cCRT in unresectable LA NSCLC – Final KN-799:
– ORR >70% (across histologies)!
– mPFS 29 and 45 mo,
– mOS 36 and 57 mo (cohort A NSCLC, B NSQ).
– Sharp discussion S. Ramella.
– UNKNOWNS: impact of RT modality and immune response.”
